Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Price & Analysis
Market: NASDAQ • Sector: Healthcare • Industry: Biotechnology
Arrowhead Pharmaceuticals, Inc. (ARWR) Profile & Business Summary
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Key Information
| Ticker | ARWR |
|---|---|
| Exchange | NASDAQ |
| Official Site | https://arrowheadpharma.com |
Market Trend Overview for ARWR
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-07-14 (ET)
As of 2026-07-14, ARWR is showing signs of slowing down. Over the longer term, the trend remains bullish.
ARWR last closed at 71.91. The price is about 2.3 ATR below its recent average price (79.58), and the market is currently in a trend that may be losing strength. Price at 71.91 is near minor support around 69.88. Momentum may slow, while light resistance sits near 72.18. View Support & Resistance from Options
The broader uptrend is still intact, but price has moved far from its recent average, increasing the risk of a pullback.
Trend score: 55 out of 100. Overall alignment is unclear. The market is currently in a late-stage trend that may be losing strength. The longer-term trend is still positive, but short-term signals are not yet confirming it.
Price is stretched well below its recent average (about 2.3 ATR). Downside extension is elevated, and chasing weakness here carries a higher rebound risk.
A key downside risk boundary is near 68.21. If price falls below this area, the current structure would likely weaken further.
On 2026-07-14, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-07-09] Price moved quickly and looked strong, but participation was limited.
Recent price action continues to trend lower in a relatively orderly manner, with no clear signs of structural stabilization yet emerging.
Selling pressure increased into the close, but price action remained uneven and lacked clean continuation.
The model still sees a directional lean, but the edge is not thick enough after adjusting for reward/risk.
The model does not deploy this setup because the directional lean exists, but the edge is still not thick enough after risk adjustment, reward/risk remains too thin at -0.14 after adjustment, recent price behavior has shown failed reversal memory, there is meaningful next-session pullback or digestion risk, and the setup already looks stretched. Predictability is 52%, agreement is 91%, and reversal risk is 29%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This reading is based on the last 20 trading days of 15-minute price, volume, and VWAP data. Price is trading 10.3% below the recent estimated cost basis of 80.14, so the recent structure is still leaning under pressure. Price is below the main cost band (78.79 to 84.49), and roughly 100% of recent positioning remains under water. That means rebounds can still run into supply from trapped holders. The broader structure still looks stretched on the weak side, so recovery attempts may need more proof before improving the tone. The next higher selling area sits around 72.53 to 74.35, and overhead supply looks fairly concentrated there. The main cost band is fairly wide relative to recent ATR, so this structure may behave less cleanly than a tighter setup. From a trading point of view, this setup remains tougher until price can reclaim the lower edge of the main cost band near 78.79.